ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ)
$45.32 -0.27 (-0.5922%)
Analysed ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ) News Sources
Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho
06-04-2026
yahoo.com
Assessing Enliven Therapeutics (ELVN) Valuation After Strong Recent Share Price Momentum
30-03-2026
yahoo.com
Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million
28-03-2026
fool.com
Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts ‘Upbeat’
26-03-2026
yahoo.com
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
03-03-2026
yahoo.com
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
25-02-2026
yahoo.com
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k
01-02-2026
fool.com
Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging Phase 1b ENABLE Trial Data
09-01-2026
yahoo.com
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones
08-01-2026
yahoo.com
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development
07-01-2026
yahoo.com
What is the current price of ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ)?
The current price of ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ) is $45.32.
ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ) absolute price change since previous trading day?
The absolute price change of ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ) since the previous trading day is $-0.27.
ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ) percentage price change since previous trading day?
The percentage price change of ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ) since the previous trading day is -0.5922%.
What is the most recent average sentiment score for ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ)?
The most recent average sentiment score for ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ) is 91 out of 100.
What is the most recent average sentiment for ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ)?
The most recent sentiment for ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ) is .
SEC-8K** Filing Available For ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.